Literature DB >> 28463395

Clinical relevance of circulating anti-ENA and anti-dsDNA secreting cells from SLE patients and their dependence on STAT-3 activation.

Raquel de la Varga Martínez1,2, Beatriz Rodríguez-Bayona3, Gustavo A Añez4, Fermín Medina Varo4, José J Pérez Venegas5, José A Brieva1, Carmen Rodríguez2.   

Abstract

Disturbances of plasma cell homeostasis and auto-antibody production are hallmarks of systemic lupus erythematosus. The aim of this study was to explore the presence of circulating anti-ENA and anti-dsDNA antibody-secreting cells, to determine their dependence on plasma cell-niche cytokines and to analyze their clinical value. The study was performed in SLE patients with serum anti-ENA and/or anti-dsDNA antibodies (n = 57). Enriched B-cell fractions and sorted antibody-secreting cells (CD19low CD38high ) were obtained from blood. dsDNA- and ENA-specific antibody-secreting cells were identified as cells capable of active auto-antibody production in culture. The addition of a combination of IL-6, IL-21, BAFF, APRIL, and CXCL12 to the cultures significantly augmented auto-antibody production and antibody-secreting cell proliferation, whereas it diminished apoptosis. The effect on auto-antibody production was dependent on STAT-3 activation as it was abrogated in the presence of the JAK/STAT-3 pathway inhibitors ruxolitinib and stattic. Among patients with serum anti-dsDNA antibodies, the detection of circulating anti-dsDNA-antibody-secreting cells was associated with higher disease activity markers. In conclusion, auto-antibody production in response to plasma cell-niche cytokines that are usually at high levels in SLE patients is dependent on JAK/STAT-3 activation. Thus, patients with circulating anti-dsDNA antibody-secreting cells and active disease could potentially benefit from therapies targeting the JAK/STAT3 pathway.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Anti-ENA; Anti-dsDNA; Antibody-secreting cells; Cytokines; Plasma cell niche; SLE; STAT-3

Mesh:

Substances:

Year:  2017        PMID: 28463395     DOI: 10.1002/eji.201646872

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

Review 1.  Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.

Authors:  Alessia Alunno; Ivan Padjen; Antonis Fanouriakis; Dimitrios T Boumpas
Journal:  Cells       Date:  2019-08-15       Impact factor: 6.600

2.  Prolactin Rescues Immature B Cells from Apoptosis-Induced BCR-Aggregation through STAT3, Bcl2a1a, Bcl2l2, and Birc5 in Lupus-Prone MRL/lpr Mice.

Authors:  Rocio Flores-Fernández; Angélica Aponte-López; Mayra C Suárez-Arriaga; Patricia Gorocica-Rosete; Alberto Pizaña-Venegas; Luis Chávez-Sanchéz; Francico Blanco-Favela; Ezequiel M Fuentes-Pananá; Adriana K Chávez-Rueda
Journal:  Cells       Date:  2021-02-04       Impact factor: 6.600

3.  Th cytokine profile in childhood-onset systemic lupus erythematosus.

Authors:  Wei Quan; Jingnan An; Gang Li; Guanghui Qian; Meifang Jin; Chenxi Feng; Si Li; Xiaozhong Li; Yunyun Xu; Xiaohan Hu
Journal:  BMC Pediatr       Date:  2021-04-21       Impact factor: 2.125

4.  Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib.

Authors:  Yu-Lan Chen; Li-Xiong Liu; Qin Huang; Xue-Ying Li; Xiao-Ping Hong; Dong-Zhou Liu
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

Review 5.  Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?

Authors:  Patricia Richter; Anca Cardoneanu; Alexandra Maria Burlui; Luana Andreea Macovei; Ioana Bratoiu; Oana Nicoleta Buliga-Finis; Elena Rezus
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.